cancer

Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

TOKYO, Jan 18, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21. Notable data include... » read more

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

LONDON AND HONG KONG, Jan 11, 2023 – (ACN Newswire via SEAPRWire.com) – Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics recently acquired a majority stake in, has received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company’s... » read more

Alercell Is All Set to Launch a Leukemia Diagnostic Test Lena Q51(R)

Bozeman, MT, December 29, 2022 – (SEAPRWire) – Alercell is all set to launch LENA Q51(R) in January 2023. A leukemia diagnostic test based on sequencing DNA will detect up to 51 Genes mutations in Leukemia patients. Alercell is on a mission of making a significant difference in the fight against cancer by offering unique and precise diagnostic solutions... » read more

Prenetics Acquires ACT Genomics; First M&A Deal since IPO, Set to Expand Footprint in Cancer Genomics

HONG KONG, Dec 16, 2022 – (ACN Newswire via SEAPRWire.com) – Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, is acquiring a majority stake of ACT, an Asia based genomics company specializing in precision oncology with operations in Hong Kong, Taiwan, Japan, Singapore, Thailand and the... » read more

Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

TOKYO, Dec 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, “eribulin”) will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from... » read more

Claudin18.2, a shining star in gastric cancer, Transcenta’s TST001 stands at the global forefront

HONG KONG, Sep 28, 2022 – (ACN Newswire via SEAPRWire.com) – Transcenta Holding Limited (06628.HK), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced that interim safety and efficacy data of dose expansion cohort from the phase I/II study of TST001 (Osemitamab), a humanized ADCC-enhanced anti-Claudin18.2... » read more

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

TOKYO, Sep 12, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301 and Study304) evaluating the efficacy of eribulin mesylate (marketed as HALAVEN) versus other chemotherapies (Treatment of Physician’s Choice [TPC], capecitabine, and vinorelbine,... » read more

Potential New Therapeutic Approach for Pancreatic Cancer is proposed at 2022 Keystone Meeting: Blocking Obesity or Fatty Acid Oxidation

Seoul, Korea, September 08, 2022 – (SEAPRWire) – In “the immunometabolism at the crossroads of obesity and cancer, Keystone Symposia (Sept. 5-9, 2022, Keystone, Co, USA)”, Dr. Soo-Youl Kim, Principal Scientist of the National Cancer Center of South Korea, showed that cancer obtains energy absolutely by burning fatty acids from blood as well as that obesity causes cancer... » read more

New Horizon Health Announced 2022 Interim Report: Revenue Up 414% YoY, Gross Margin Climbs to 82%

HANGZHOU, Aug 19, 2022 – (ACN Newswire via SEAPRWire.com) – New Horizon Health (6606.HK), China’s leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today. Based on the financial information before the audit as of June 30, 2022, New Horizon Health achieved total revenue of RMB226... » read more

Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies

Ingelheim, Germany and Singapore, Jun 2, 2022 – (ACN Newswire via SEAPRWire.com) – Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.... » read more

Fujitsu and Southern Tohoku General Hospital start joint research on AI technology for detecting pancreatic cancer from non-contrast CT scans

TOKYO, Apr 25, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu and the Southern Tohoku General Hospital today announced the launch of a joint research project with Fujitsu Japan Limited (hereinafter Fujitsu Japan)(1) and FCOM CORPORATION (hereinafter FCOM)(2) on an AI technology for the early detection of pancreatic cancer from computed tomography (CT) scans without... » read more

诺辉健康发布2021年报：营收同比增长202%，毛利率攀升至72.7%

HANGZHOU, Mar 18, 2022 – (亚太商讯 via SEAPRWire.com) – 中国领先的癌症早筛生物高科技公司诺辉健康（6606.HK）今日发布2021年截至12月31日的年度业绩报告。 诺...

NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets

Oslo (Norway)/Tokyo (Japan) and Basel (Switzerland)/Mannheim (Germany), Mar 9, 2022 – (JCN Newswire via SEAPRWire.com) – NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech company focused on developing an oral plug and play DNA vaccination technology to stimulate patients’ cytotoxic T-cells targeting a wide range of cancer-related antigens,... » read more

Fujitsu and Tokyo Medical and Dental University leverage world’s fastest supercomputer and AI technology for scientific discovery to shed light on drug resistance in cancer treatment

TOKYO, Mar 7, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu and the Tokyo Medical and Dental University (TMDU) today announced a new technology that uses AI to discover new causal mechanisms of drug resistance in cancer treatments from clinical data. Leveraging the world’s fastest supercomputer “Fugaku,”(1) the new technology enables high-speed calculation of 20,000... » read more

Causes Week 2021: Raising awareness for cancer research

BostonGene and NEC Announce Global Partnership

TOKYO, JAPAN and WALTHAM, Mass., Dec 15, 2021 – (JCN Newswire via SEAPRWire.com) – BostonGene Corporation and NEC Corporation (TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer new windowBostonGene Tumor Portrait Tests in key international markets, including Japan as the first market outside of the U.S. BostonGene’s... » read more

Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium

TOKYO, Dec 6, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eribulin mesylate (product name: Halaven, halichondrin class microtubule dynamics inhibitor, “eribulin”), MORAb-202, an antibody drug conjugate (ADC), and H3B-6545 (selective estrogen alpha receptor covalent antagonist), discovered by... » read more

Stomach cancer ‘atlas’ could map paths to better treatment options

SINGAPORE – To have a more sophisticated understanding of gastric cancer, scientists here have created an intricate atlas of these cancer cells to offer more insight into how they can spread within the body. The map goes into granular detail on how specific molecular pathways can drive cancer growth, while also providing insight on how... » read more

Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment

TOKYO, Oct 19, 2021 – (JCN Newswire via SEAPRWire.com) – Aichi Cancer Center (1) and Fujitsu Limited today announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients’ individual cancer types and various genomic variants (2). Figure1. The newly developed system The effectiveness... » read more

New pill offers hope to patients with aggressive form of breast cancer

SINGAPORE – An orally consumed anti-cancer drug known as Bexarotene offers new hope to patients with triple-negative breast cancer (TNBC) – an aggressive form of breast cancer that appears more frequently among women below 40. This drug has been found to be able to tame highly aggressive and invasive breast cancer cells by converting them... » read more